Almirall splits chairman and CEO roles
This article was originally published in Scrip
The Spanish pharmaceutical company Almirall has appointed Eduardo Sanchiz, currently its chief executive of corporate development and finance, its new CEO. Mr Sanchiz will take up the position on 1 July. The move comes after the firm's current CEO and chairman, Jorge Gallardo, proposed to the board that these two roles be separated. Mr Sanchiz took up his current post at Almirall in 2004 after serving 22 years at Lilly working in a variety of roles in finance, marketing, business development and general management. Mr Gallardo was appointed the firm's CEO in 1997 and then chairman and CEO in 2001. He will continue as executive chairman.
You may also be interested in...
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.